PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35424647-1	2022	A technique of obtaining plexitonic structures based on Ag2S quantum dots passivated with l-cysteine (Ag2S/l-Cys QDs) in the presence of Au nanorods passivated with cetyltrimethylammonium bromide molecules (Au/CTAB NRs) with controlled luminescence properties has been developed.	Cetrimonium	210-214	angiotensin II receptor type 1	Homo sapiens	102-106	
35424647-2	2022	The structural and luminescence properties of Ag2S/l-Cys QDs with Au/CTAB NRs are studied.	Cetrimonium	69-73	angiotensin II receptor type 1	Homo sapiens	46-50	
35424647-7	2022	With weak plexcitonic coupling in the nanostructures (Ag2S QD/l-Cys)/(polyDADMAC)/(Au/CTAB NRs), the possibility of increasing the quantum yield of trap state luminescence for Ag2S QDs due to the Purcell effect has been demonstrated.	Cetrimonium	86-90	angiotensin II receptor type 1	Homo sapiens	54-58	
35424647-7	2022	With weak plexcitonic coupling in the nanostructures (Ag2S QD/l-Cys)/(polyDADMAC)/(Au/CTAB NRs), the possibility of increasing the quantum yield of trap state luminescence for Ag2S QDs due to the Purcell effect has been demonstrated.	Cetrimonium	86-90	angiotensin II receptor type 1	Homo sapiens	176-180	
35424647-8	2022	In the case of formation (Ag2S QD/l-Cys)/(polyDADMAC)/(Au/CTAB NRs) a transformation of shallow trap state structure was established using the thermostimulated luminescence method.	Cetrimonium	58-62	angiotensin II receptor type 1	Homo sapiens	26-30	
35209443-1	2022	The luminescence properties of Ag2S quantum dots passivated with L-Cysteine (Ag2S/L-Cys QDs) are studied in the presence of Au nanorods passivated with cetyltrimethylammonium bromide molecules (Au/CTAB NRs).	Cetrimonium	197-201	angiotensin II receptor type 1	Homo sapiens	77-81	
35209443-6	2022	With weak plexcitonic coupling in the nanostructures (Ag2S QD/L-Cys)/(PolyDADMAC)/(Au/CTAB NRs), the possibility of increasing the quantum yield of trap state luminescence for Ag2S QDs due to the Purcell effect has been demonstrated.	Cetrimonium	86-90	angiotensin II receptor type 1	Homo sapiens	54-58	
35209443-6	2022	With weak plexcitonic coupling in the nanostructures (Ag2S QD/L-Cys)/(PolyDADMAC)/(Au/CTAB NRs), the possibility of increasing the quantum yield of trap state luminescence for Ag2S QDs due to the Purcell effect has been demonstrated.	Cetrimonium	86-90	angiotensin II receptor type 1	Homo sapiens	176-180	
33134004-1	2020	We report the synthesis of alpha-Ag2S nanoparticles (NPs) by one-step laser ablation of a silver target in aqueous solution of thiourea (Tu, CH4N2S) mixed with cationic cetyltrimethylammonium bromide (CTAB) as surfactant.	Cetrimonium	169-199	angiotensin II receptor type 1	Homo sapiens	33-37	
33134004-1	2020	We report the synthesis of alpha-Ag2S nanoparticles (NPs) by one-step laser ablation of a silver target in aqueous solution of thiourea (Tu, CH4N2S) mixed with cationic cetyltrimethylammonium bromide (CTAB) as surfactant.	Cetrimonium	201-205	angiotensin II receptor type 1	Homo sapiens	33-37	
33134004-2	2020	The effect of the CTAB surfactant on the structural, morphological, optical, and elemental composition of Ag2S NPs was evaluated using X-ray diffraction (XRD), transmission electron microscopy (TEM), scanning electron microscopy (SEM), energy-dispersive X-ray spectroscopy (EDX), and UV-vis spectroscopy.	Cetrimonium	18-22	angiotensin II receptor type 1	Homo sapiens	106-110	
33134004-3	2020	The optical absorption decreased and the optical energy gap of alpha-Ag2S increased from 1.5 to 2 eV after the CTAB surfactant was added to the Tu solution.	Cetrimonium	111-115	angiotensin II receptor type 1	Homo sapiens	69-73	
33134004-4	2020	XRD studies revealed that the synthesized Ag2S NPs were polycrystalline with a monoclinic structure and that crystallinity of the nanoparticles was improved after adding CTAB.	Cetrimonium	170-174	angiotensin II receptor type 1	Homo sapiens	42-46	
33134004-6	2020	Scanning electron microscopy investigations confirmed the production of monodisperse Ag2S NPs when using the CTAB surfactant.	Cetrimonium	109-113	angiotensin II receptor type 1	Homo sapiens	85-89	
33237737-2	2020	Herein, a biodegradable hollow SiO2-based nanosystem (Ag2S-GOx@BHS NYs) is developed by a novel one-step dual-template (bovine serum albumin (BSA) and cetyltrimethylammonium bromide (CTAB)) synthetic strategy for image-guided therapy.	Cetrimonium	151-181	angiotensin II receptor type 1	Homo sapiens	54-58	
33237737-2	2020	Herein, a biodegradable hollow SiO2-based nanosystem (Ag2S-GOx@BHS NYs) is developed by a novel one-step dual-template (bovine serum albumin (BSA) and cetyltrimethylammonium bromide (CTAB)) synthetic strategy for image-guided therapy.	Cetrimonium	183-187	angiotensin II receptor type 1	Homo sapiens	54-58